Fluent Financial LLC Sells 6,399 Shares of Biogen Inc. $BIIB

Fluent Financial LLC reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 25.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 19,144 shares of the biotechnology company’s stock after selling 6,399 shares during the quarter. Biogen makes up 1.3% of Fluent Financial LLC’s holdings, making the stock its 27th largest holding. Fluent Financial LLC’s holdings in Biogen were worth $3,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of BIIB. Elevation Point Wealth Partners LLC acquired a new stake in Biogen in the 2nd quarter worth $25,000. Accredited Wealth Management LLC raised its position in shares of Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 185 shares during the last quarter. WFA of San Diego LLC acquired a new position in shares of Biogen during the second quarter valued at about $32,000. True Wealth Design LLC lifted its stake in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 90 shares during the period. Finally, GoalVest Advisory LLC bought a new stake in shares of Biogen in the fourth quarter valued at about $35,000. 87.93% of the stock is owned by institutional investors.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.18% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

BIIB has been the topic of several research reports. The Goldman Sachs Group restated a “buy” rating on shares of Biogen in a research note on Monday, February 9th. BMO Capital Markets raised their price objective on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Morgan Stanley set a $190.00 price objective on Biogen in a report on Sunday, February 8th. Wolfe Research set a $231.00 price objective on Biogen in a research report on Monday, February 9th. Finally, Mizuho upped their target price on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Twelve analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biogen currently has a consensus rating of “Hold” and an average price target of $205.31.

Biogen Stock Down 3.8%

Shares of BIIB opened at $183.84 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a 50-day moving average price of $185.36 and a two-hundred day moving average price of $170.24. The stock has a market cap of $26.98 billion, a price-to-earnings ratio of 20.87, a P/E/G ratio of 1.46 and a beta of 0.15. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same period in the prior year, the company posted $3.44 earnings per share. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts predict that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.